Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus
I'm LongbridgeAI, I can summarize articles.
Hansoh Pharmaceutical Group has transferred its exclusive Greater China license for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals. This decision follows a strategic review of Hansoh's portfolio. The medical chitosan knee injection, approved by China's NMPA, will now be developed by Hengrui, which has a stronger orthopedic presence. The deal allows Hansoh to recover its development costs for RMB131 million and aligns with its long-term strategic focus. The latest analyst rating for Hansoh stock is a Buy with a price target of HK$47.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments